Vunakizumab

View Clinical trials for Vunakizumab Get Vunakizumab Patent Info for Free

Jiangsu Hengrui Medicine was granted CFDA approval to start clinical trials of SHR-1314, an injected drug aimed at treating autoimmune diseases. Hengrui will initially test the drug in psoriasis patients. The drug is an independently developed humanized mAb that targets IL-17A and hinders signal transduction, reducing the inflammatory response.

Inn NameVunakizumab
Lab CodesSHR-1314
Chemical NameGamma1 heavy chain (1-453) [humanized VH (Homo sapiens IGHV1-2*02 (82.70%) -(IGHD)-IGHJ4*01) [8.8.16] (1-123) -Homo sapiens IGHG1*01, G1m17, nG1m1 (CH1 (124-221), hinge (222 236),CH2 (237-346), CH3 D12>E (362), L14>M (364) (347-451), CHS (452-453)) (124-453)], (226-213')-disulfide with kappa light chain (1’-213’) [humanized V-KAPPA (Homo sapiens IGKV6-21*01 (80.00%) -IGKJ1*01) [5.3.9] (1'-106') -Homo sapiens IGKC*01, Km3 (107'-213')]; dimer (232-232":235-235")-bisdisulfide
Alternate NameImmunoglobulin G1, anti-(interleukin) (human-mus musculus monoclonal SHR-1314 heavy chain), disulfide with human-mus musculus monoclonal SHR-1314 light chain, dimer
SequenceHeavy chain
EVQLVQSGAE VKKPGASVKV SCKASGYTFT DYEVHWVRQA PGQGLEWMGV 50
IDPGTGGVAY NQKFEGRVTM TADTSTSTAY MELRSLRSDD TAVYYCTRYS 100
LFYGSSPYAM DYWGQGTLVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200
TQTYICNVNH KPSNTKVDKK VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP 250
PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 300
QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR 350
EPQVYTLPPS REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT 400
PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS 450
PGK 453

Light chain
EIVLTQSPDF QSVTPKEKVT ITCSASSSVN YMHWFQQKPD QSPKLWIYRT 50
SNLASGVPSR FSGSGSGTDY TLTINSLEAE DAATYYCQQR SSYPWTFGQG 100
TKLEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC 213

Disulfide bridges location
Intra-H (C23-C104) 22-96 150-206 267-327 373-431
22''-96'' 150''-206'' 267''-327'' 373''-431''
Intra-L (C23-C104) 23'-87' 133'-193'
23'''-87''' 133'''-193'''
Inter-H-L (h 5-CL 126) 226-213' 226''-213'''
Inter-H-H (h 11, h 14) 232-232'' 235-235''

N-glycosylation sites
H CH2 N84.4:
303, 303''
Fucosylated complex bi-antennary CHO-type glycans
Other post-translational modifications
H CHS K2 C-terminal lysine clipping:
453, 453''
Chemical StructureVunakizumab.png
Cas Registry Number1792181-33-9
OriginatorJiangsu Hengrui Medicine Co. Ltd.
Mechanism Of ActionIL-17A inhibitor
IndicationAutoimmune diseases, Psoriasis

Free counters!